Great Lakes Advisors LLC Has $4.49 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Great Lakes Advisors LLC trimmed its position in Zoetis Inc. (NYSE:ZTSFree Report) by 46.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,761 shares of the company’s stock after selling 19,625 shares during the quarter. Great Lakes Advisors LLC’s holdings in Zoetis were worth $4,492,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. First National Advisers LLC raised its holdings in shares of Zoetis by 45.2% in the 4th quarter. First National Advisers LLC now owns 13,714 shares of the company’s stock worth $2,707,000 after buying an additional 4,269 shares in the last quarter. Private Wealth Management Group LLC acquired a new position in Zoetis in the fourth quarter valued at about $33,000. Montrusco Bolton Investments Inc. increased its holdings in shares of Zoetis by 56.0% during the fourth quarter. Montrusco Bolton Investments Inc. now owns 330,251 shares of the company’s stock worth $65,182,000 after buying an additional 118,556 shares in the last quarter. First Heartland Consultants Inc. acquired a new position in shares of Zoetis in the 4th quarter worth approximately $470,000. Finally, Meridian Wealth Management LLC increased its holdings in Zoetis by 18.4% during the 4th quarter. Meridian Wealth Management LLC now owns 1,541 shares of the company’s stock valued at $304,000 after purchasing an additional 239 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. The Goldman Sachs Group lowered their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. HSBC lowered their target price on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Stifel Nicolaus cut their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 30th. Barclays reduced their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Finally, Piper Sandler reiterated an “overweight” rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average price target of $211.75.

Check Out Our Latest Analysis on Zoetis

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Zoetis Trading Up 0.2 %

NYSE:ZTS opened at $174.06 on Monday. The company has a market cap of $79.42 billion, a P/E ratio of 33.54, a price-to-earnings-growth ratio of 2.70 and a beta of 0.86. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The business has a 50 day moving average price of $164.65 and a two-hundred day moving average price of $179.52. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTSGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.04. The company had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. Zoetis’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.31 EPS. As a group, analysts expect that Zoetis Inc. will post 5.77 EPS for the current fiscal year.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.